Gemigliptin/metformin - LG Chem
Alternative Names: FDC (gemigliptin/metformin HCl sustained release) - LG Chem; Metformin/gemigliptin; ZemiMet SRLatest Information Update: 28 Sep 2023
At a glance
- Originator LG Life Sciences
- Developer LG Chem
- Class Antihyperglycaemics; Biguanides; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors; Glucose modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Thailand (PO, Tablet)
- 23 Mar 2020 LG Chem plans a phase I bioequivalence trial (In volunteers) in July 2020 (PO,Controlled release) in July 2020 (NCT04317703)
- 27 Aug 2019 LG Chem plans a phase I bioavailability study for Type 2 diabetes mellitus (In volunteers) in November 2019 (PO) (NCT04070794)